Satellos Bioscience, which trades on the NASDAQ and TSX under the symbol MSLE, has been assigned an International Nonproprietary Name (INN) by the World Health Organization for its drug candidate formerly designated SAT-3247. The compound will now be referred to as Forazapadin.
Forazapadin is an orally administered small molecule designed to restore muscle regeneration and repair biology through inhibition of the AAK1 protein. By blocking AAK1, the candidate re-establishes a biochemical signal required to support muscle regeneration. Satellos is developing the drug as a potential treatment for Duchenne muscular dystrophy (DMD) that operates independently of dystrophin, meaning it could apply to patients regardless of their specific exon mutation status.
The compound is currently being evaluated in two Phase 2 studies in DMD patients: BASECAMP, a randomized, placebo-controlled study enrolling pediatric participants, and TRAILHEAD, an open-label study in adult participants. Satellos expects completion of enrollment in the BASECAMP trial this quarter, with clinical data anticipated in the fourth quarter.
In addition to its DMD program, Satellos plans to initiate a Phase 2 clinical trial for Forazapadin in facioscapulohumeral muscular dystrophy (FSHD) by the end of 2026.
